Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume
Status:
Unknown status
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
This multicentre, open-label, single-arm Study is to evaluate the effect of Rosuvastatin 20
mg 76 weeks on coronary atherosclerosis plaque versus baseline in Chinese coronary heart
disease (CHD) patients with hyperlipidemia by measuring the plaque volume using a 64 slice
spiral CT. Effect on blood lipids, hsCRP and Carotid intima-media thickness (CIMT) is also
evaluated.